Hims & Hers Now Offers Affordable Generic Semaglutide in Canada
Hims & Hers offers cheaper generic semaglutide in Canada ($149/mo) with medical support for weight loss care.
/ 352 items
#XY Event-Driven Stocks↓
Eli Lilly’s Retatrutide Delivers 28.3% Weight Loss in Phase 3 Trial, Analysts Stay Bullish
Eli Lilly’s retatrutide delivered 28.3% average weight loss at 80 weeks in Phase 3, with some patients reaching over 30% at 104 weeks. Analysts at Truist, Wolfe, and RBC stay bullish.
Medtronic to Acquire SPR Therapeutics for $650M to Expand Chronic Pain Treatment Options
Medtronic will buy SPR Therapeutics for a 60-day device that uses gentle nerve signals to reduce chronic pain without drugs.
BioMarin Plans FDA Submission After Positive VOXZOGO Hypochondroplasia Trial
BioMarin’s VOXZOGO improved growth in children with hypochondroplasia, showing strong trial results and good safety.
Lilly Buys Engage Bio for $202M to Unlock Safer, Repeatable DNA Therapies
Eli Lilly buys Engage Bio for up to $202M to boost safer gene therapy using non-viral DNA delivery technology.
Jupiter Neurosciences Signs $100M Deal for Next-Gen MDMA Therapy
Jupiter secured $100M rights to sell safer MDMA drug ALA-002 in the US, targeting mental health treatment growth.